Breaking News Instant updates and real-time market news.

KITE

Kite Pharma

$55.66

-0.75 (-1.33%)

11:02
10/07/16
10/07
11:02
10/07/16
11:02

Kite Pharma sees reporting added data on durability of response to KTE-C19

Kite Pharma announced updated results from the Phase 1 portion of Kite's ZUMA-1 clinical trial of its lead product candidate, KTE-C19, in patients with chemorefractory, aggressive non-Hodgkin lymphoma, NHL.The results were provided in an oral presentation at the European Society for Medical Oncology, ESMO, annual congress. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor (CAR) that is designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. "These data complement our recently reported interim topline results from ZUMA-1 Phase 2 and support the potential for KTE-C19 to be a breakthrough therapy for chemorefractory, aggressive NHL," said David Chang, M.D., Ph.D., Executive Vice President, Research and Development, and Chief Medical Officer of Kite. "We are encouraged that the complete remission rate of 43 percent in the Phase 1 portion of the study continues through month 12 and look forward to reporting additional data on the durability of response to KTE-C19 from the Phase 2 portion of ZUMA-1 in 2017."

  • 07

    Oct

  • 18

    Oct

  • 06

    Nov

KITE Kite Pharma
$55.66

-0.75 (-1.33%)

09/27/16
COWN
09/27/16
NO CHANGE
COWN
Outperform
Efficacy of Kite's KTE-C19 'impressive,' safety 'acceptable,' says Cowen
Cowen analyst Eric Schmidt thinks the 33% complete remissions rate at three months in chemorefractory aggressive NHL patients in Kite Pharma's ZUMA-1 trial is "impressive" and that the safety experience in the trial is "acceptable." The two deaths reported in the trial need to be considered not only in the context of the treatment's efficacy but also in the context of the disease, said Schmidt, who continues to model KTE-C19 as a greater than $1B product and keeps an Outperform rating on Kite Pharma shares.
09/27/16
STFL
09/27/16
NO CHANGE
STFL
Kite Pharma data much better than standard of care, says Stifel
Stifel analyst Thomas Shrader says that Kite reported a complete response rate of 52% for its KTE-C19 drug in DLBCL, versus the standard of care's complete response rate of about 8%. The analyst says that the results exceed the level needed for FDA approval. He keeps a $74 price target and Buy rating on the shares.
09/27/16
LEER
09/27/16
NO CHANGE
LEER
Outperform
Kite's ZUMA-1 interim data incrementally positive for Juno, says Leerink
Leerink analyst Michael Schmidt says Kite Pharma's (KITE) top-line interim results from its pivotal ZUMA-1 trial of anti-CD19 CAR-T product KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma, or DLBCL, are incrementally positive for Juno Therapeutics (JUNO). While Juno is roughly one year behind Kite in DLBCL, the analyst believes its JCAR017 holds the promise to have a compelling safety/efficacy profile in lymphoma and Acute Lymphoblastic Leukemia. He reiterates an Outperform rating on Juno's shares.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

MU

Micron

$32.50

0.77 (2.43%)

06:36
06/27/17
06/27
06:36
06/27/17
06:36
Hot Stocks
Micron exploring sale of discontinued Lexar business »

Micron Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 29

    Aug

MON

Monsanto

$117.80

0.78 (0.67%)

06:33
06/27/17
06/27
06:33
06/27/17
06:33
Downgrade
Monsanto rating change  »

Monsanto downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

FMSA

Fairmount Santrol

$3.68

-0.05 (-1.34%)

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Downgrade
Fairmount Santrol rating change  »

Fairmount Santrol…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGO

Assured Guaranty

$41.55

0.9 (2.21%)

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Hot Stocks
S&P affirms Assured Guaranty's AA financial strength ratings with stable outlook »

Assured Guaranty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FET

Forum Energy

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Downgrade
Forum Energy rating change  »

Forum Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$65.89

-0.04 (-0.06%)

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Downgrade
Schlumberger rating change  »

Schlumberger downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

HP

Helmerich & Payne

$53.16

0.42 (0.80%)

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Downgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPN

Superior Energy

$9.78

0.04 (0.41%)

06:31
06/27/17
06/27
06:31
06/27/17
06:31
Downgrade
Superior Energy rating change  »

Superior Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBR

Nabors Industries

$7.93

0.06 (0.76%)

06:31
06/27/17
06/27
06:31
06/27/17
06:31
Downgrade
Nabors Industries rating change  »

Nabors Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHI

Baker Hughes

$53.70

-0.29 (-0.54%)

06:31
06/27/17
06/27
06:31
06/27/17
06:31
Downgrade
Baker Hughes rating change  »

Baker Hughes downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PI

Impinj

$59.37

0.58 (0.99%)

06:31
06/27/17
06/27
06:31
06/27/17
06:31
Downgrade
Impinj rating change  »

Impinj downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GEF

Greif

$55.51

-0.1 (-0.18%)

06:29
06/27/17
06/27
06:29
06/27/17
06:29
Conference/Events
Greif to host investor breakfast day »

Investor Breakfast Day to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

UAA

Under Armour

$21.56

0.36 (1.70%)

, UA

Under Armour

$19.92

0.27 (1.37%)

06:27
06/27/17
06/27
06:27
06/27/17
06:27
Recommendations
Under Armour, Under Armour, Kohl's, Nike, adidas analyst commentary  »

Under Armour still…

UAA

Under Armour

$21.56

0.36 (1.70%)

UA

Under Armour

$19.92

0.27 (1.37%)

KSS

Kohl's

$37.52

0.49 (1.32%)

NKE

Nike

$53.28

0.43 (0.81%)

ADDYY

adidas

$94.38

-0.015 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

LYV

Live Nation

$34.86

0.02 (0.06%)

06:20
06/27/17
06/27
06:20
06/27/17
06:20
Recommendations
Live Nation analyst commentary  »

Live Nation price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLT

Hilton

$65.23

-0.17 (-0.26%)

, CHH

Choice Hotels

$66.25

-0.45 (-0.67%)

06:17
06/27/17
06/27
06:17
06/27/17
06:17
Recommendations
Hilton, Choice Hotels, Hyatt, Marriott analyst commentary  »

Deutsche…

HLT

Hilton

$65.23

-0.17 (-0.26%)

CHH

Choice Hotels

$66.25

-0.45 (-0.67%)

H

Hyatt

$58.09

0.39 (0.68%)

MAR

Marriott

$103.93

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

GOOGL

Alphabet Class A

$972.09

-14 (-1.42%)

06:14
06/27/17
06/27
06:14
06/27/17
06:14
Technical Analysis
Technical View: Alphabet Class A falls after EU fine, potential bearish pattern »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSUR

OraSure

$15.72

0.17 (1.09%)

06:10
06/27/17
06/27
06:10
06/27/17
06:10
Hot Stocks
OraSure's HIV self-test supported by Gates Foundation for accelerated adoption »

OraSure entered a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

BABA

Alibaba

$142.73

-0.28 (-0.20%)

06:09
06/27/17
06/27
06:09
06/27/17
06:09
Initiation
Alibaba initiated  »

Alibaba resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

RDWR

Radware

$17.94

-0.04 (-0.22%)

06:06
06/27/17
06/27
06:06
06/27/17
06:06
Hot Stocks
Radware granted ISO27017 and ISO27018 cloud services certifications »

Radware has achieved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jul

  • 13

    Jul

GRPN

Groupon

$3.45

-0.02 (-0.58%)

06:06
06/27/17
06/27
06:06
06/27/17
06:06
Recommendations
Groupon analyst commentary  »

Groupon trading well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDS

GDS Holdings

$8.83

-0.22 (-2.43%)

, BABA

Alibaba

$142.73

-0.28 (-0.20%)

06:05
06/27/17
06/27
06:05
06/27/17
06:05
Hot Stocks
GDS Holdings announces new order from Alibaba for Beijing 3 data center »

GDS Holdings (GDS)…

GDS

GDS Holdings

$8.83

-0.22 (-2.43%)

BABA

Alibaba

$142.73

-0.28 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

MCK

McKesson

$167.61

0.65 (0.39%)

06:04
06/27/17
06/27
06:04
06/27/17
06:04
Conference/Events
McKesson to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 26

    Jul

  • 30

    Jul

INFO

IHS Markit

$46.40

-0.15 (-0.32%)

06:04
06/27/17
06/27
06:04
06/27/17
06:04
Earnings
IHS Markit sees FY17 adjusted EPS $2.02-$2.08, consensus $2.06 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

UCBI

United Community Banks

$26.70

0.22 (0.83%)

, FOFN

Four Oaks Fincorp

$15.18

0.4 (2.71%)

06:03
06/27/17
06/27
06:03
06/27/17
06:03
Hot Stocks
United Community, Banks Four Oaks Fincorp announce merger agreement »

Community Banks (UCBI)…

UCBI

United Community Banks

$26.70

0.22 (0.83%)

FOFN

Four Oaks Fincorp

$15.18

0.4 (2.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$8.01

-0.04 (-0.50%)

, CMCSA

Comcast

$39.59

0.09 (0.23%)

06:03
06/27/17
06/27
06:03
06/27/17
06:03
Periodicals
Sprint enters wireless deal talks with Comcast, Charter, WSJ says »

Sprint (S) is negotiating…

S

Sprint

$8.01

-0.04 (-0.50%)

CMCSA

Comcast

$39.59

0.09 (0.23%)

CHTR

Charter

$332.65

1.85 (0.56%)

TMUS

T-Mobile

$63.15

-0.25 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 03

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.